SEP-363856 is an agent of orally active and CNS active psychotropic with a unique, non-D2/5-HT2A mechanism of action, exerts its antipsychotic-like effects, has the potential to treatment of schizophrenia.

5-HT1A receptor:2.3 μM （EC50）, 5-HT2C receptor:30 μM （EC50）, 5-HT1D receptor:0.262 μM （EC50）, 5-HT2A receptor:10 μM （EC50）, 5-HT1B receptor:15.6 μM （EC50）, 5-HT7 receptor:6.7 μM （EC50）, TAAR1:0.140 μM （EC50）

SEP-856 (10μM) specifically inhibits α2A, α2B, D2, 5-HT1A, 5-HT1B, 5-HT1D, 5-HT2A, 5-HT2B, 5-HT2C and 5-HT7> 50% receptor.

SEP-856 (0.3, 1 and 10 mg/kg, i.p.) is CNS active. SEP-856 exhibits a behavioral signature similar to known antipsychotic drugs.PCP-induced hyperactivitysignificantly reduced by SEP-856 (0.3, 1 and 10 mg/kg, orally once) . Oral SEP-856 administration (1, 3 and 10 mg/kg) produces a dosedependent decrease in REM sleep, increase in latency to REM sleep and increase in cumulative wake (W) time.